According to a Federal Register notice, the United States Trade Representative (USTR) has extended 81 COVID-related medical-care product Section 301 tariff exclusions for an additional six months. The exclusions were set to expire on May 31, 2022, and are now scheduled to expire on November 30, 2022.
According to the Notice, “In light of the continuing efforts to combat COVID-19, the U.S. Trade Representative has determined that a 6-month extension of the 81 COVID-19-related product exclusions is warranted. The U.S. Trade Representative’s decision to extend the 81 product exclusions takes into account public comments previously provided, and the advice of advisory committees and the interagency Section 301 Committee.”
The USTR may continue to consider further extensions and additional modifications as deemed appropriate.
Source PwC
Latest Posts in "United States"
- U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally
- Streamlined Sales Tax: Is It the Right Fit for Every Business?
- FISC Hearing on Tax Implications of Trump Administration Policies September 23
- USA Simplified Sales Tax Program: E-commerce Benefits and Drawbacks Analysis
- Canada removing tariffs on certain US goods; Canadian business support measures announced
